by NMS Group | Nov 17, 2025 | 2025, News
Nerviano (Milan), Italy – Shanghai, China 17 November 2025 — Nerviano Medical Sciences (NMS), a clinical-stage biopharmaceutical company focused on oncology innovation, today announced that its subsidiary, Nerviano Medical Sciences (Shanghai) Co., Ltd. (NMS China),...
by NMS Group | Nov 7, 2025 | 2025, News
Nerviano (Milan), Italy, 7 November 2025 – Nerviano Medical Sciences S.r.l. (NMS), a member of NMS Group S.p.A. and a clinical-stage biotech company discovering and developing innovative therapies for the treatment of cancer, presented its poster at the World ADC...
by NMS Group | Oct 27, 2025 | 2025, Events, News
Nerviano Medical Sciences Srl is excited to announce its participation in BIO-Europe 2025, one of the premier partnering conferences for the global biotechnology and pharmaceutical industry. The event, taking place in Vienna, Austria, November 3–5, 2025, brings...
by NMS Group | Oct 2, 2025 | 2025, Events, News, Uncategorized
Nerviano Medical Sciences (NMS) ADC Business Unit Portfolio Head, Rosita Lupi, delivered an oral presentation at the Festival of Biologics in Basel (30/09/2025): “Reinventing Cytotoxins and Targeted Molecules as Next-Generation Payloads for ADCs.” The session was very...
by NMS Group | Aug 1, 2025 | 2025, News
Nerviano, Italy – Shanghai, China 1 August 2025 — Nerviano Medical Sciences Srl (NMS Srl or NMS), a clinical stage biopharmaceutical leader in oncology innovation, announced today the expansion of its presence in Asia with the establishment of Nerviano Medical...
by NMS Group | Jul 28, 2025 | 2025, News
NERVIANO, Italy, 24 July 2025 — Accelera, a global leader in preclinical in vivo toxicology and contract research services, today announced the appointment of Dr. Silvia Guionaud, PhD, DECVP, as Chief Executive Officer, effective immediately. Dr. Guionaud brings more...
Welcome and Check out our new motion picture!
Recent Comments